Interpace Biosciences Inc.

11/18/2026 | Press release | Distributed by Public on 11/18/2026 16:00

Registration Withdrawal (Form RW)

Interpace Biosciences, Inc.

Waterview Plaza, Suite 310

2001 Route 46

Parsippany, NJ 07054

November 18, 2026

Via EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549

Re: Interpace Biosciences, Inc.
Withdrawal of Registration Statement on Form S-1
File No. 333-299123

Ladies and Gentlemen:

Pursuant to Rule 477 promulgated under the Securities Act of 1933, as amended (the "Securities Act"), Interpace Biosciences, Inc. (the "Registrant") hereby respectfully requests that the U.S. Securities and Exchange Commission (the "Commission") consent to the withdrawal, effective as of the date hereof or at the earliest practicable date hereafter, of the Registrant's Registration Statement on Form S-1 (File No. 333-299123), together with all exhibits and amendments thereto (collectively, the "Registration Statement") initially filed with the Commission on September 25, 2026, and subsequently amended on October 1, 2026 and October 30, 2026.

The grounds for this application for withdrawal are that, due to current market conditions, the Registrant has determined not to pursue the public offering to which the Registration Statement relates at this time. The Registrant confirms that no securities have been sold pursuant to the Registration Statement. Accordingly, withdrawal of the Registration Statement is consistent with the public interest and the protection of investors, as contemplated by paragraph (a) of Rule 477.

The Registrant requests that all fees paid to the Commission in connection with the filing of the Registration Statement be credited for future use.

Thank you for your attention to this matter. Should you have any questions regarding these matters, please do not hesitate to contact Todd Kornfeld of McDermott Will & Schulte LLP at (212) 547-5890.

Sincerely,
Interpace Biosciences, Inc.
By: /s/ Thomas W. Burnell
Name: Thomas W. Burnell
Title: President and Chief Executive Officer
Cc: Merrill M. Kraines, Esq., McDermott Will & Schulte LLP
Todd R. Kornfeld, Esq., McDermott Will & Schulte LLP
Interpace Biosciences Inc. published this content on November 18, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on November 18, 2026 at 22:00 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]